# Biobanking and Biomarker Validation (BBV) Core

> **NIH NIH P20** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2021 · $222,126

## Abstract

COBRE Kansas Institute for Precision Medicine (KIPM) – “Biobanking and Biomarker Validation Core” 
ABSTRACT 
The overall objective of the “Kansas Institute for Precision Medicine” (KIPM) COBRE at the University of Kansas 
Medical Center (KUMC) is to advance the customization of healthcare through promoting innovative scientific 
discoveries. We have entered the era of Precision Medicine, an initiative recently announced as part of the 21st 
Century Cures Act, which is focused on using the molecular basis of diseases to better match patients with the 
appropriate therapies and care resulting in improved outcomes. To advance this mission, we have established 
the Biobanking and Biomarker Validation (BBV) Core, which combines exceptional expertise and essential 
resources within established infrastructure, i.e., Biospecimen Repository Core Facility (BRCF), the Biomarker 
Discovery Laboratory (BDL), and the Clinical Molecular Oncology Laboratory (CMOL). Access to the BBV core 
will strengthen the biomedical research capacity of our COBRE faculty by enhancing their research base and 
infrastructure capacities. To advance precision medicine research within this COBRE, the BBV core will 1) 
Provide centralized and uniform collections, processing, and storage of tissue and bodily fluids and tissue-related 
histology services; 2) provide integral and comprehensive protein and nucleic acid isolation, quantitation, and 
molecular characterization services; and 3) provide fully customizable molecular testing and genomic-based 
sequencing services. The BBV core is designed to centralize these essential services that will in turn provide 
support to the KIPM COBRE faculty, pilot grantees, and researchers within our region and beyond. Given the 
level of sophistication of the materials and services required for the range of studies proposed within the KIPM 
COBRE, a highly integrated BBV core is not only cost effective but an absolute necessity. The BBV core 
eliminates redundant infrastructure and expense required for each researcher to develop their own capabilities 
or to search for the necessary research expertise. The BBV core will enable multiple COBRE faculty and future 
pilot grantees, access to state-of-the-art facilities and laboratory expertise, thereby further reducing the relative 
cost of their studies. Furthermore, the BBV core will continue to provide in-kind technical staff-support and 
banking resources, which help the KIPM COBRE faculty to more effectively utilize their funding, both institutional 
startup and COBRE support. The success of the BBV core and ultimately the COBRE faculty is essential to 
advancing the mission of the KIPM to advance the customization of healthcare through promoting innovative 
scientific discoveries.

## Key facts

- **NIH application ID:** 10115115
- **Project number:** 5P20GM130423-03
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** ANDREW K. GODWIN
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $222,126
- **Award type:** 5
- **Project period:** 2019-02-15 → 2024-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10115115

## Citation

> US National Institutes of Health, RePORTER application 10115115, Biobanking and Biomarker Validation (BBV) Core (5P20GM130423-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10115115. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*